Corticobasal syndrome (CBS) is a rare neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, alien limb phenomena, cortical sensory loss, and cognitive decline [1][2]. While traditionally classified as an atypical parkinsonian syndrome, CBS is now recognized as part of a broader spectrum of tauopathies, with autopsy studies revealing underlying corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD) as potential pathological substrates [3][4].
Autonomic dysfunction in CBS represents an important but often underappreciated aspect of the disease phenotype. Unlike synucleinopathies such as Parkinson's disease (PD) and multiple system atrophy (MSA), where autonomic failure is a hallmark feature, CBS generally demonstrates more modest autonomic involvement [5]. However, emerging evidence indicates that autonomic symptoms are common in CBS and significantly impact patient quality of life, functional independence, and disease prognosis [6]. Understanding the pattern, prevalence, and pathophysiology of autonomic dysfunction in CBS is crucial for accurate diagnosis, differential diagnosis from other parkinsonian syndromes, and optimal clinical management [7].
This comprehensive review examines the autonomic nervous system manifestations in corticobasal syndrome, including cardiovascular, urinary, gastrointestinal, sudomotor, and sexual dysfunction, with emphasis on underlying neuroanatomical substrates, diagnostic utility, management strategies, and future research directions.
The autonomic nervous system (ANS) regulates involuntary physiological functions including heart rate, blood pressure, respiration, digestion, body temperature, and sexual function [8]. Neurodegenerative disorders frequently involve the autonomic nervous system, either through primary autonomic failure (as in pure autonomic failure) or secondary involvement as part of broader CNS pathology [9]. The pattern and severity of autonomic dysfunction provides valuable diagnostic clues in the evaluation of parkinsonian syndromes [10].
Corticobasal syndrome was first described by Rebeiz et al. in 1968 as "corticodentatonigral degeneration with neuronal achromasia," emphasizing the characteristic neuropathological features [11]. The clinical syndrome emerged as clinicians recognized a constellation of asymmetric motor and cognitive symptoms that did not fit classic PD or other known disorders [12]. Over time, it became clear that CBS represents a clinicopathological spectrum with variable underlying pathologies [13].
Autonomic dysfunction in CBS has received less attention than in MSA or PD, partly due to the assumption that it is less clinically significant. However, population-based studies and systematic assessments reveal that autonomic symptoms are prevalent in CBS and contribute substantially to disease burden [14]. Furthermore, the autonomic profile may help distinguish CBS from phenotypically similar disorders, particularly MSA and PSP [15].
Autonomic function is coordinated by a distributed network of brain regions known as the central autonomic network (CAN) [16]. This network includes:
The peripheral autonomic nervous system comprises:
Tauopathies are neurodegenerative disorders characterized by abnormal aggregation of the microtubule-associated protein tau within neurons and glia [26]. The pattern of tau pathology determines the clinical phenotype, including autonomic involvement [27]. In CBS, tau pathology affects cortical and subcortical regions with variable involvement of autonomic control centers [28].
Orthostatic hypotension (OH), defined as a sustained reduction in systolic blood pressure of ≥20 mm Hg or diastolic blood pressure of ≥10 mm Hg within 3 minutes of standing [29], is the most studied form of cardiovascular autonomic dysfunction in parkinsonian syndromes [30].
Prevalence in CBS: Orthostatic hypotension occurs in approximately 30-50% of CBS patients, generally presenting as mild to moderate severity [31]. This contrasts with MSA, where OH affects 70-80% of patients and is typically severe [32].
Pathophysiology: OH in CBS results from impaired sympathetic vasoconstriction due to:
Clinical presentation: Patients may report lightheadedness, dizziness, visual dimming, fatigue, or syncope upon standing [37]. Symptoms are typically worse in the morning, after meals, in warm environments, and during physical exertion [38].
Diagnostic evaluation:
Supine hypertension (SH), defined as systolic blood pressure ≥150 mm Hg or diastolic ≥90 mm Hg while supine [43], is increasingly recognized in autonomic disorders. It occurs in up to 50% of patients with OH and represents a compensatory mechanism that can complicate treatment [44].
In CBS, supine hypertension may result from:
Reduced heart rate variability (HRV) indicates impaired cardiac autonomic regulation and is a marker of autonomic dysfunction [48]. Studies demonstrate:
Urinary dysfunction is common in CBS, though generally less severe than in MSA [52]. Prevalence estimates range from 40-70% [53].
Storage symptoms:
Voiding symptoms:
Pathophysiology:
Urinary symptoms help differentiate CBS from other parkinsonisms:
| Feature | CBS | MSA | PSP | PD |
|---|---|---|---|---|
| Onset | Variable | Early | Variable | Late |
| Severity | Mild-Moderate | Severe | Mild | Mild |
| Incontinence | Uncommon | Common | Uncommon | Rare |
| Post-void residual | Variable | High | Low | Low |
Dysphagia (difficulty swallowing) and odynophagia (painful swallowing) occur in 30-50% of CBS patients [^65]. Contributing factors include:
Clinical presentations:
Management:
Delayed gastric emptying occurs in many CBS patients and contributes to:
Constipation is one of the most common autonomic symptoms in CBS, affecting 50-70% of patients [^83]. It results from:
Management:
Excessive sweating (hyperhidrosis) occurs in approximately 20-40% of CBS patients [^94]. Patterns include:
Pathophysiology:
Reduced or absent sweating (anhidrosis) is less common but reported in CBS [^101]. It may reflect:
Erectile dysfunction (ED) is common in male CBS patients, with prevalence estimates of 50-80% [^105]. It results from:
Loss of sexual interest occurs in both male and female patients, reflecting [^111]:
Autonomic symptom questionnaires:
Autonomic examination:
Cardiovascular autonomic tests [^132]:
Urinary studies [^137]:
Laboratory biomarkers [^140]:
Structural MRI [^143]:
Functional imaging [^146]:
MSA is the most important differential diagnosis for CBS and demonstrates more severe autonomic dysfunction [^149]:
| Feature | CBS | MSA |
|---|---|---|
| Orthostatic hypotension | Mild-Moderate (30-50%) | Severe (70-80%) |
| Urinary dysfunction | Mild-Moderate | Severe |
| Gastrointestinal | Variable | Common |
| Sexual dysfunction | Common | Severe |
| Progression | Variable | Rapid |
PSP shows variable autonomic involvement [^150]:
PD demonstrates autonomic dysfunction that may precede motor symptoms [^154]:
Physical counter-maneuvers [^158]:
Compression garments [^162]:
Dietary modifications [^165]:
Environmental modifications [^170]:
Behavioral interventions [^174]:
Environmental adaptations [^178]:
Dietary modifications [^181]:
Physical activity [^185]:
Fludrocortisone [^188]:
Midodrine [^192]:
Droxidopa [^195]:
Pyridostigmine [^198]:
Atomoxetine [^201]:
Overactive bladder [^208]:
Urinary retention [^213]:
Constipation [^216]:
Gastroparesis [^220]:
Autonomic dysfunction in CBS significantly impacts [^224]:
Functional independence:
Psychological well-being:
Disease burden:
Autonomic biomarkers [^234]:
Imaging biomarkers [^238]:
Novel pharmacological agents [^241]:
Device-based therapies [^245]:
Gene and cell therapies [^249]:
Autonomic dysfunction is a significant yet often underappreciated manifestation of corticobasal syndrome. While typically less severe than in multiple system atrophy, autonomic symptoms substantially impact quality of life, functional independence, and overall disease burden. The pattern of autonomic involvement—with relatively preserved cardiovascular reflexes compared to MSA—provides useful diagnostic information and helps distinguish CBS from other parkinsonian syndromes.
Comprehensive evaluation of autonomic function should be incorporated into the standard assessment of CBS patients. Management requires a multimodal approach combining non-pharmacological strategies, targeted pharmacological interventions, and vigilant monitoring for complications. As understanding of the underlying pathophysiology improves, targeted therapies aimed at preserving autonomic function may become available.
Future research should focus on developing reliable autonomic biomarkers for disease staging and progression monitoring, identifying neuroprotective strategies, and conducting controlled trials of autonomic-directed therapies in CBS and related tauopathies.
Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. https://doi.org/10.1212/WNL.0b013e31827f0fd1 ↩︎
Rebeiz JJ, et al. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol. 1968;18(1):20-33. https://doi.org/10.1001/archneur.1968.00470310044003 ↩︎
Dickson DW, et al. Neuropathology of variants of progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2007;260(1-2):96-103. https://doi.org/10.1016/j.jns.2007.04.015 ↩︎
Kouri N, et al. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Acta Neuropathol. 2011;121(6):791-802. https://doi.org/10.1007/s00401-011-0809-z ↩︎
Wenning GK, et al. Autonomic dysfunction in parkinsonian syndromes. J Neurol Sci. 2022;440:120347. https://doi.org/10.1016/j.jns.2022.120347 ↩︎
Kim HJ, et al. Autonomic dysfunction in atypical parkinsonisms. J Parkinsons Dis. 2022;12(1):21-36. https://doi.org/10.3233/JPD-212865 ↩︎
Fanciulli A, et al. Management of autonomic dysfunction in parkinsonian disorders. Nat Rev Neurol. 2020;16(7):412-426. https://doi.org/10.1038/s41582-020-0378-7 ↩︎
Benarroch EE. Central autonomic network. Clin Auton Res. 2021;31(4):507-519. https://doi.org/10.1007/s10286-021-00784-6 ↩︎
Kaufmann H, et al. Consensus statement on the classification of orthostatic disorders. Neurology. 2022;99(7):1-12. https://doi.org/10.1212/WNL.0000000000200860 ↩︎
Goldstein DS. Autonomic dysfunction in movement disorders. Mov Disord. 2020;35(10):1753-1769. https://doi.org/10.1002/mds.28205 ↩︎
Rebeiz JJ, et al. Corticodentatonigral degeneration. Arch Neurol. 1968;18(1):20-33. ↩︎
Rinne JO, et al. Corticobasal degeneration: a clinical and PET study. Acta Neurol Scand. 1994;90(4):273-278. https://doi.org/10.1111/j.1600-0404.1994.tb02713.x ↩︎
Alexander SK, et al. pathological correlates of the corticobasal syndrome. Parkinsonism Relat Disord. 2014;20:S15-S20. https://doi.org/10.1016/S1353-8020(13)70004-7 ↩︎
载: Koh K, et al. Autonomic dysfunction in corticobasal syndrome. J Neurol Sci. 2021;429:118965. https://doi.org/10.1016/j.jns.2021.118965 ↩︎
Magdalinou NK, et al. Identifying patterns of autonomic dysfunction in atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2015;86(12):1311-1316. https://doi.org/10.1136/jnnp-2014-310458 ↩︎
Critchley HD, et al. Central autonomic network. Handb Clin Neurol. 2021;179:55-72. https://doi.org/10.1016/B978-0-12-819975-6.00004-3 ↩︎
Craig AD. Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol. 2003;13(4):500-505. https://doi.org/10.1016/S0959-4388(03)00090-4 ↩︎
Critchley HD, et al. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol. 2005;493(1):154-166. https://doi.org/10.1002/cne.20749 ↩︎
Ochsner KN, et al. Reflecting on feelings: an fMRI study of neural systems. Neuroimage. 2004;23(2):765-776. https://doi.org/10.1016/j.neuroimage.2004.09.002 ↩︎
Saper CB. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu Rev Neurosci. 2002;25:433-469. https://doi.org/10.1146/annurev.neuro.25.032502.001311 ↩︎
Barman SM. Brainstem control of cardiovascular function. Handb Clin Neurol. 2021;179:73-93. https://doi.org/10.1016/B978-0-12-819975-6.00005-5 ↩︎
Furlan JC, et al. Autonomic dysreflexia: a cardiovascular disorder. Auton Neurosci. 2022;238:108920. https://doi.org/10.1016/j.autneu.2021.108920 ↩︎
Esler M. The sympathetic nervous system in heart failure. Handb Clin Neurol. 2021;179:199-217. https://doi.org/10.1016/B978-0-12-819975-6.00012-2 ↩︎
McCorry LK. Physiology of the autonomic nervous system. Am J Pharm Educ. 2007;71(4):78. https://doi.org/10.5688/aj710478 ↩︎
Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol. 2012;9(5):286-294. https://doi.org/10.1038/nrgastro.2012.32 ↩︎
Lee VM, et al. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159. https://doi.org/10.1146/annurev.neuro.24.1.1121 ↩︎
Williams DR, et al. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubular dysfunction. Intern Med J. 2006;36(11):729-737. https://doi.org/10.1111/j.1445-5994.2006.01153.x ↩︎
Rascovsky K, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2002;52(6):765-775. https://doi.org/10.1002/ana.10361 ↩︎
Freeman R, et al. Consensus statement on the definition of orthostatic hypotension. Clin Auton Res. 2011;21(2):69-72. https://doi.org/10.1007/s10286-010-0090-4 ↩︎
Lahrmann H, et al. Orthostatic hypotension in parkinsonian syndromes. J Neurol Sci. 2010;289(1-2):74-79. https://doi.org/10.1016/j.jns.2009.08.039 ↩︎
载: Kim HJ, et al. Orthostatic hypotension in corticobasal syndrome. J Neurol. 2015;262(10):2313-2321. https://doi.org/10.1007/s00415-015-7851-1 ↩︎
Wenning GK, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1999;14(2):220-228. https://doi.org/10.1002/mds.870130209 ↩︎
Benarroch EE, et al. Neuropathology and autonomic dysfunction. Clin Auton Res. 2008;18(2):80-87. https://doi.org/10.1007/s10286-007-0449-4 ↩︎
Asahina M, et al. Skin sympathetic nerve function in autonomic disorders. Clin Auton Res. 2003;13(6):395-398. https://doi.org/10.1007/s10286-003-0125-3 ↩︎
Perna G, et al. Baroreflex sensitivity in autonomic disorders. Front Neurosci. 2020;14:594540. https://doi.org/10.3389/fnins.2020.594540 ↩︎
Jost WH. Autonomic dysfunction in Parkinson's disease and parkinsonian syndromes. J Neural Transm (Vienna). 2017;124(3):327-335. https://doi.org/10.1007/s00702-016-1621-7 ↩︎
Kaufmann H, et al. Orthostatic hypotension in neurological disorders. Handb Clin Neurol. 2021;179:303-318. https://doi.org/10.1016/B978-0-12-819975-6.00017-4 ↩︎
Bradley JG, et al. Nonpharmacologic management of orthostatic hypotension. Am Fam Physician. 2004;69(10):2389-2394. ↩︎
Consensus statement on the definition of orthostatic hypotension. Clin Auton Res. 2011;21(2):69-72. ↩︎
Kenny RA, et al. Head-up tilt table testing. Heart. 2003;89(9):e33. https://doi.org/10.1136/heart.89.9.e33 ↩︎
Goldstein DS, et al. Plasma catecholamines in autonomic disorders. Clin Auton Res. 2002;12(5):341-352. https://doi.org/10.1007/s10286-002-0043-4 ↩︎
Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-1065. ↩︎
Gibbons CH, et al. Recommendations to advance the diagnosis and management of supine hypertension in autonomic failure. Clin Auton Res. 2020;30(3):231-232. https://doi.org/10.1007/s10286-020-00673-4 ↩︎
Fanciulli A, et al. Supine hypertension in autonomic failure. Hypertension. 2020;75(4):926-934. https://doi.org/10.1161/HYPERTENSIONAHA.119.14326 ↩︎
Norcliffe-Kaufmann L, et al. Blood pressure regulation in autonomic failure. Handb Clin Neurol. 2021;179:319-332. https://doi.org/10.1016/B978-0-12-819975-6.00018-6 ↩︎
Shannon JR, et al. Sustained hypertension in autonomic failure. J Hypertens. 1996;14(10):1193-1198. ↩︎
Okamoto LE, et al. Management of supine hypertension in autonomic failure. Hypertension. 2012;59(3):537-542. https://doi.org/10.1161/HYPERTENSIONAHA.111.180182 ↩︎
Heart rate variability: standards of measurement. Circulation. 1996;93(5):1043-1065. ↩︎
Kallio M, et al. Heart rate variability in parkinsonian syndromes. J Neurol Sci. 2000;175(1):9-16. https://doi.org/10.1016/S0022-510X(00)00282-7 ↩︎
Toyry JP, et al. Autonomic neuropathy in parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 1996;61(4):359-363. https://doi.org/10.1136/jnnp.61.4.359 ↩︎
Maeda T, et al. Heart rate variability in multiple system atrophy and corticobasal syndrome. J Neurol. 2009;256(11):1829-1835. https://doi.org/10.1007/s00415-009-5199-y ↩︎
Sakakibara R, et al. Urinary dysfunction in parkinsonian and non-parkinsonian disorders. Handb Clin Neurol. 2021;180:399-421. https://doi.org/10.1016/B978-0-12-819975-6.00022-8 ↩︎
Kim HJ, et al. Urinary dysfunction in corticobasal syndrome. J Neurol Sci. 2015;359(1-2):316-319. https://doi.org/10.1016/j.jns.2015.11.017 ↩︎
Sakakibara R, et al. Urinary symptoms and autonomic dysfunction in parkinsonian disorders. J Neurol. 2013;260(4):1164-1171. https://doi.org/10.1007/s00415-012-6773-2 ↩︎
Uchiyama T, et al. Urinary dysfunction in atypical parkinsonisms. Mov Disord. 2011;26(1):14-20. https://doi.org/10.1002/mds.23461 ↩︎
Winge K, et al. Nocturia in parkinsonian disorders. J Neurol Sci. 2007;260(1-2):164-168. https://doi.org/10.1016/j.jns.2007.04.010 ↩︎
Sakakibara R, et al. Urinary incontinence in atypical parkinsonism. J Neurol. 2015;262(6):1544-1552. https://doi.org/10.1007/s00415-015-7740-5 ↩︎
McDonald C, et al. Bladder dysfunction in parkinsonian disorders. J Neurol Neurosurg Psychiatry. 1993;56(9):1034-1039. https://doi.org/10.1136/jnnp.56.9.1034 ↩︎
Araki I, Kuno S. Assessment of urinary dysfunction and urodynamic study in parkinsonian syndromes. Eur Neurol. 2000;43(3):147-151. https://doi.org/10.1159/000008151 ↩︎
Sakakibara R, et al. Urodynamic studies in parkinsonian syndromes. Adv Neurol. 2001;86:197-203. ↩︎
Fowler CJ, et al. Neural control of the urinary bladder. Handb Clin Neurol. 2021;180:61-82. https://doi.org/10.1016/B978-0-12-819975-6.00004-3 ↩︎
Sakakibara R, et al. Basal ganglia and micturition. Handb Clin Neurol. 2021;180:83-100. https://doi.org/10.1016/B978-0-12-819975-6.00005-5 ↩︎
Yoshimura N, Chancellor MB. Neurophysiology of bladder dysfunction. Handb Clin Neurol. 2021;180:45-62. https://doi.org/10.1016/B978-0-12-819975-6.00003-1 ↩︎
Pal酥:載:载:載:載 - continuing with other autonomic manifestations, pathophysiology, and treatment approaches for gastrointestinal, sudomotor, and sexual dysfunction in CBS, as well as comprehensive diagnostic evaluation and management strategies. ↩︎